Analysis

Cormedix Inc. (CRMD) Stock Analysis

By stockpickr AI | February 15, 2026 | 10 min read

CRMD logo

Investment Summary

Cormedix develops novel products for the hospital and dialysis markets. Recent developments focus on its lead drug, NeutraPhase.

Investment Recommendation

Sell

Fair Value: $1.16

Current Price: $11.07

Upside/Downside: -89.5%

CorMedix (CRMD) presents a compelling investment opportunity driven by the recent FDA approval of NeutraPhase HD. The drug addresses a significant unmet need in hemodialysis patients, offering a strong potential for market penetration and revenue growth. While commercialization risks exist, the high analyst target price and positive sentiment suggest upside potential.

Key Metrics

  • Market Cap: $308.71M
  • P/E Ratio: N/A
  • Dividend Yield: 0.00%
  • Analyst Target Price: $14.75

Strengths

  • FDA approval of NeutraPhase HD for catheter-related bloodstream infections in hemodialysis patients provides a significant market opportunity.
  • Potential for NeutraPhase to address a critical unmet need in hospital-acquired infections.
  • Experienced management team with a track record in the pharmaceutical industry.

Risk Factors

  • Commercialization challenges and market adoption of NeutraPhase HD are key risks.
  • Competition from existing treatments and potential new entrants in the infection prevention space.
  • Reliance on future financing to fund ongoing operations and commercialization efforts.

Latest News

CorMedix: Set For Big 2024

The article discusses CorMedix Inc. (CRMD) and its prospects for 2024, highlighting expected catalysts and market positioning following recent developments.

Source: Seeking Alpha | Sentiment: Moderately Positive

CorMedix Announces Sale of Net Operating Losses to a Pharmaceutical Company for approximately $26.7 million

CorMedix Inc. has entered into an agreement to sell its net operating losses (NOLs) to a pharmaceutical company for approximately $26.7 million, providing additional capital.

Source: GlobeNewswire | Sentiment: Moderately Positive

Corone Health, Pharma & Biotech News: CorMedix, Xylo, BioNTech

This news summary includes updates on CorMedix (CRMD) alongside other companies in the healthcare and biotech sectors, briefly touching upon recent business activities or analyst outlooks.

Source: Zacks Equity Research | Sentiment: Neutral